For: | Mellinghoff IK, Cloughesy TF. Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. J Clin Oncol 2022;40:3510-9. [PMID: 35201903 DOI: 10.1200/JCO.21.02166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Brem S, Henderson F Jr, Bagley SJ, Desai AS. Commentary: Complementary and Alternative Medicine for Gliomas: Systematic Review and Critical Appraisal of Current Literature. Neurosurgery 2023;92:e46-7. [PMID: 36693123 DOI: 10.1227/neu.0000000000002328] [Reference Citation Analysis] |
2 | Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA 2023;329:574-87. [PMID: 36809318 DOI: 10.1001/jama.2023.0023] [Reference Citation Analysis] |
3 | Sun S, Gu W, Wu H, Zhao Q, Qian S, Xiao H, Yang K, Liu J, Jin Y, Hu C, Gao Y, Xu H, Liu H, Ji J, Chen Y. Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection. Adv Funct Materials. [DOI: 10.1002/adfm.202205038] [Reference Citation Analysis] |